Identifying markers for effective treatment of Myasthenia Gravis with complement inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients with generalized Myasthenia Gravis who are positive for anti-AChR antibodies. It aims to identify specific markers that indicate a favorable response to complement inhibitor therapy, which has been recently approved for treatment. The study will involve monitoring patients who meet the eligibility criteria and require therapy with these drugs, assessing their clinical outcomes and biological responses. The findings could help tailor treatments for better patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years;
* Diagnosis of generalized anti-AChR positive Myasthenia Gravis;
* Need for therapy with complement inhibitor drugs according to the therapeutic indications approved by AIFA (16);
* Ability to perform follow-up at the reference center;
* Signed informed consent to the study.

Exclusion Criteria:

* Age \<18 years;
* Poor compliance with drug therapy;
* Concomitant autoimmune diseases;
* Insufficient availability of clinical information;
* Ongoing neoplasia or infection at the time of biological sample collection;
* Refusal to sign the informed consent to the study

Where it's running

• Fondazione Policlinico Universitario A. Gemelli IRCCS
  Roma, Italy Recruiting

Study contacts

• Principal investigator: Raffaele Iorio — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Study coordinator: Raffaele Iorio, MD, PhD
• Email: raffaele.iorio@policlinicogemelli.it
• Phone: +390630154807

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Panorama: Neuromuscular Organoids to understand refractory AChR+ myasthenia gravis

  This study tests neuromuscular organoids built from stem cells to see if they reveal why some people with AChR-positive myasthenia gravis don’t respond to standard treatments.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07717281

• Claseprubart in adults with generalized myasthenia gravis

  This study tests whether claseprubart can help adults with generalized myasthenia gravis when compared with placebo.

  Recruiting at 11 sites Phase 3 Dianthus Therapeutics · Pasadena, California and 11 other locations · NCT07647510

• Aritinercept for generalized myasthenia gravis

  This study tests whether aritinercept is safe and helpful for adults with generalized myasthenia gravis compared with placebo.

  Recruiting at 11 sites Phase 1/2 Aurinia Pharmaceuticals Inc. · Pasadena, California and 10 other locations · NCT07596901

• MyoSense 360 in generalized myasthenia gravis: testing digital monitoring to track change

  This study tests whether a digital monitoring system can detect meaningful changes in generalized myasthenia gravis over a year in adult patients using a smartphone app and wearable device.

  Recruiting at 2 sites Ad scientiam · Aarhus and 19 other locations · NCT07323316

• Corticosteroid-sparing efgartigimod for elderly AChR-positive generalized myasthenia gravis

  This trial tests whether efgartigimod given IV or under the skin helps people 65 and older with AChR-positive generalized myasthenia gravis reduce their corticosteroid dose while keeping symptoms under control.

  Recruiting at 8 sites Phase 4 Centre Hospitalier Universitaire de Nice · Nice, Alpes-Maritimes and 8 other locations · NCT07072988

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.